Medtronic India Launches Symplicity Spyral System to Tackle High Blood Pressure

The Medtronic RDN program, with a track record involving over 25,000 patients globally, has been studied in various conditions, demonstrating significant and sustained reductions in blood pressure. The procedure has proven to be safe, with minimal adverse events.

Medtronic India, a wholly-owned subsidiary of Medtronic plc, has introduced the Symplicity Spyral renal denervation system (RDN) as a solution for addressing high blood pressure.

The minimally invasive procedure targets nerves near the kidneys that can become overactive, leading to elevated blood pressure.

Commenting on the same, Michael Blackwell, vice president and managing director of Medtronic India, said, "The recent FDA approval for the RDN system and an update earlier this year of the European Hypertension Society (ESH) guidelines highlight the role of RDN in hypertension care. We are excited to offer this therapy to all eligible patients in India."

The Symplicity Spyral blood pressure procedure has demonstrated clinical efficacy in reducing high blood pressure, thereby mitigating serious health risks. The recently FDA-approved system, a result of a decade of clinical research and development, has also received approval from Indian regulatory authorities.

The procedure involves a small incision and the insertion of a thin tube (catheter) into the artery leading to the kidney. Through the catheter, the doctor regulates the excessive activity of nerves connected to the kidney. Notably, no implant is left behind after the tube is removed.

The Medtronic RDN program, with a track record involving over 25,000 patients globally, has been studied in various conditions, demonstrating significant and sustained reductions in blood pressure. The procedure has proven to be safe, with minimal adverse events.

In a strategic move earlier this year, Medtronic India collaborated with Qure.ai to integrate AI for advanced stroke management. This partnership aimed to provide comprehensive stroke care solutions, leveraging Medtronic's neuroscience expertise and Qure.ai's AI-enabled innovations.

The objective of the collaboration was to offer AI solutions to comprehensive and primary stroke centers, establishing a network to facilitate faster identification, decision-making, and triaging of stroke patients. The ultimate goal was to improve patient outcomes through efficient use of technology.

In another initiative, Medtronic India, in association with Fortis Escorts Heart Institute, launched the nationwide campaign 'Reset the Beat.' The campaign focuses on increasing awareness about sudden cardiac arrest (SCA) and cardiopulmonary resuscitation (CPR), with plans to extend its reach to leading hospitals across India.